Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma.

J Immunother Cancer · 2017 · PMC5696743 · PMID 29157311

Europe PMC DOI

hedged sentences

0.0004

closest p · 0.0× alpha

0.0004

boldest claim

The sentences

highly significantp = 0.0004actually significant

These groups demonstrated highly significant improvements in OS (Bm2 hi /CCL3 lo HR = 0.14 (95%CI:0.04–0.49) p = 0.0004; Bm2 hi /CCL4 lo HR = 0.21 (95%CI:0.08–0.57), p = 0.001; and Bm2 hi /CXCL8 lo HR = 0.29 (95%CI:0.11–0.76), p = 0.007, Figure 5 ).

also in 132,142 other papers

did not reach statistical significanceno p-value reported

Lack of PD-L1 expression (<5%) was most frequently observed in irPD (10/12 samples (83%) were PD-L1 negative) compared to SD (1/4 samples (25%) and PR + CR (3/6 samples (50%) were PD-L1 negative) but this did not reach statistical significance (Additional file 2 : Table S4).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.